The evolution of lung cancer screening

In the 1970s, four trials failed to demonstrate any mortality reduction using a combination of chest X‐ray (CXR) and/or sputum cytology. The recent early lung cancer action project (ELCAP) demonstrated that modern screening is capable of detecting Stage I lung cancers. Bronchial epithelial changes l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 2003-12, Vol.84 (4), p.234-238
Hauptverfasser:	Wilkinson, Neal W., Loewen, Gregory M., Klippenstein, Donald L., Litwin, Alan M., Anderson, Timothy M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Biological Evolution Bronchoscopy chest X-ray computed tomography Cytodiagnosis Diagnostic Tests, Routine - trends fluorescence bronchoscopy Humans Lung - diagnostic imaging lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - pathology Male Medical sciences molecular markers Pneumology Randomized Controlled Trials as Topic screening Sensitivity and Specificity Smoking - adverse effects Sputum - cytology Survival Analysis Tomography, X-Ray Computed - trends Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the 1970s, four trials failed to demonstrate any mortality reduction using a combination of chest X‐ray (CXR) and/or sputum cytology. The recent early lung cancer action project (ELCAP) demonstrated that modern screening is capable of detecting Stage I lung cancers. Bronchial epithelial changes leading up to cancers are now being understood to include histologic changes and genetic alterations. Emerging molecular markers detected in sputum and serum show promise in the future of lung cancer screening. J. Surg. Oncol. 2003;84:234–238. © 2003 Wiley‐Liss, Inc.
ISSN:	0022-4790 1096-9098
DOI:	10.1002/jso.10315